TICKERNERD
Menu
IMVTIMVTHealthcare · Biotechnology

IMVT Stock Forecast: Immunovant, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$39
−0.28% on the day

The 17 Wall Street analysts covering Immunovant, Inc. hold a median 12-month price target of $47 — +22.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.9B
Ticker Nerd rank
38 / 100
Median analyst target
$47
Analysts covering
17
Total return, dividends reinvested
1W
−3.9%
1M
−0.7%
YTD
+51.5%
1Y
+145.1%
From 52W high
−6.3%
From 52W low
+162.2%
$15
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMVT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunovant, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Volatility
76
Value
72
Accruals
45
Growth
43
Issuance
36
Quality
35
Revisions
30
Size
18

Momentum (95): The shares have been drifting up relative to others.

Revisions (30): Analysts have, on balance, been cutting their forecasts.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Immunovant, Inc. — and when they’d sell — is the membership.

Wall Street

IMVT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMVT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26IMVTHigh $66Median $47Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
13 Buy4 Hold0 Sell
Low $24Median $47High $66

The green dot is the last close — the median target sits +22.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 June 2026CitigroupMaintainsBuy$57 → $61
26 May 2026GuggenheimMaintainsBuy—
22 May 2026Truist SecuritiesMaintainsHold—
21 May 2026B of A SecuritiesMaintainsBuy—
21 May 2026HC Wainwright & Co.MaintainsBuy—
15 Apr 2026Goldman SachsMaintainsNeutral—
20 Mar 2026BernsteinInitiatesMarket Perform—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026GuggenheimMaintainsBuy—
8 Jan 2026Truist SecuritiesMaintainsHold—
6 Jan 2026Wolfe ResearchUpgradeOutperform—
15 Dec 2025Goldman SachsMaintainsNeutral—
14 Oct 2025Truist SecuritiesInitiatesHold—
30 Sept 2025JP MorganMaintainsOverweight—
4 Sept 2025HC Wainwright & Co.ReiteratesBuy—
12 Aug 2025B of A SecuritiesMaintainsBuy—
12 Aug 2025JP MorganMaintainsOverweight—
28 July 2025UBSMaintainsNeutral—
22 Apr 2025UBSDowngradeNeutral—
20 Mar 2025B of A SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

IMVT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Immunovant, Inc. (IMVT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
9.2×

Cheaper than 11% of US stocks

EV / EBITDA
−13.2×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.8%

Higher than 18% of US stocks

Return on assets
−38.4%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IMVT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMVTImmunovant, Inc.$7.9B
38
PCVXVaxcyte, Inc.$7.7B
41
IBRXImmunityBio, Inc.$7.5B
60
KYMRKymera Therapeutics, Inc.$8.2B
69
IONSIonis Pharmaceuticals, Inc.$8.3B
46
TGTXTG Therapeutics, Inc.$8.3B
61
PRAXPraxis Precision Medicines, Inc.$8.4B
28
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMVT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest IMVT news & analysis

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

Seeking Alpha · 28 July 2026positive

Seeking Alpha initiated coverage of Immunovant with a BUY rating and $50 price target, citing optimism around IMVT-1402's differentiated profile including strong IgG reduction with minimal albumin and LDL impact, with Graves' disease as the principal valuation driver.

Why it matters — An analyst's positive initiation with a $50 price target and best-in-class potential for IMVT-1402 could influence investor perception of Immunovant's key pipeline asset.

FAQ

Frequently asked questions about IMVT stock

What is the IMVT stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Immunovant, Inc. have a median 12-month price target of $47, with estimates ranging from $24 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMVT stock a buy right now?

Of the 17 analysts covering Immunovant, Inc., 13 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunovant, Inc. 38 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMVT?

As at 1 Aug 2026, Immunovant, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will IMVT stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +22.0% from the last close, and Ticker Nerd's factor model ranks Immunovant, Inc. 38 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMVT stock forecast for 2030?

No analyst covering Immunovant, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $66 over the next 12 months.

How has IMVT stock performed over the past year?

Immunovant, Inc. returned +145.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunovant, Inc. do?

Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases.

What is the latest news on IMVT?

The most recent item we track (Seeking Alpha, 28 July 2026): "Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy". Seeking Alpha initiated coverage of Immunovant with a BUY rating and $50 price target, citing optimism around IMVT-1402's differentiated profile including strong IgG reduction with minimal albumin and LDL impact, with Graves' disease as the principal valuation driver.

Company

About Immunovant, Inc.

Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Headquartered in Durham, North Carolina and founded in 2018, the company specializes in immunology and leverages anti-FcRn (neonatal Fc receptor) technology to modulate immunoglobulin G (IgG) levels in the body. Its pipeline includes investigational monoclonal antibody candidates such as batoclimab and IMVT-1402, designed to selectively target FcRn and potentially address a range of autoimmune conditions driven by pathogenic antibodies. Immunovant concentrates on creating targeted, subcutaneous treatments that can be administered in outpatient settings, aiming to provide options that fit into patients’ daily lives. Within the healthcare and biotechnology sector, Immunovant plays a role as an innovator in FcRn inhibition, collaborating closely with clinicians, regulators, and research partners to advance its clinical programs and generate data across multiple autoimmune indications.

CEO Dr. Eric Venker M.D., Pharm.D. · 315 employees · United States · https://immunovant.com